Q1 2025 net product revenue for ZORYVE® (roflumilast) was $63.8 million, a 196% increase compared to Q1 of 2024, and a 2% decrease compared to Q4 of 2024, due to typical first-quarter deductible reset ...

Good day, and welcome to Arcutis Biotherapeutics 2025 first-quarter financial results conference call. (Operator Instructions) Please be advised that today's conference is being recorded. I would now ...